Ethosuximide

Overview

Ethosuximide is antiepileptic agent. It was introduced in 1960 as the third of three marketed succinimides. its origin is in the cyclic ureide structure. It has a considerable efficasy against pentylenetetrazol seizures and was introduced as a 'pure petit mal' drug. its popularity continues, based on its safety and efficasy. its role as the first choice anti-absence drug remains undiminished, in part because of the idiosyncratic hepatotoxicity of the alternative drug, valproic acid. Ethosuximide is administered orally.

Primary Characterstics

Indications

Back to top

Pharmacokinetics

Oral absorption of Ethosuximide is found to be 97% ±2. Volume of distribution is found to be 0.7 l/kg and plasma protien binding is negligible. Presystemic metabolism is noted to be 0.00255% ±0.00155 and metabolism is reported hepatic. Renal Excretion accounts for 17-38% and plasma half life is 53-56 hr.

Back to top

Contraindications

Back to top

Drug Interactions

Back to top

Side Effects

Back to top

Dosage

Reserpine's dosage details are as follows:
Dose Single Dose Frequency Route Instructions

Adult Dosage

14.285 to 21.428 mg/kg18 (17.8565)24 hourlyPOMaintenance, As Required
750 to 1500 mg/d1100 (1125)24 hourlyPOInitially for a week

Paedriatic Dosage (20kg)

12.5 to 25 mg/kg19 (18.75)12 hourlyOralStart with low doses, and then Gradually Increase

Neonatal Dosage (3kg)

Not indicated in this age group

High Risk Groups

Back to top

Warning / Precautions

Back to top

Storage Conditions

Caps, Syrup

Store in a well closed container, Below 30°C.

Back to top

Interference in Pathology

  • Urinanalysis
  • Liver Function Test (LFT)

Back to top

Brands / Trade Names of Reserpine

Back to top

Manufacturers of Ethosuximide in Pakistan

Back to top

Previous Drug Generic - Next Drug Generic


Suggested Pages